1,836 Shares in Thermo Fisher Scientific Inc. $TMO Bought by PeakShares LLC

PeakShares LLC purchased a new stake in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor purchased 1,836 shares of the medical research company’s stock, valued at approximately $1,064,000.

A number of other hedge funds have also recently modified their holdings of the company. Corient Private Wealth LLC raised its position in Thermo Fisher Scientific by 9.0% during the 4th quarter. Corient Private Wealth LLC now owns 798,226 shares of the medical research company’s stock valued at $462,930,000 after purchasing an additional 66,029 shares during the last quarter. Auto Owners Insurance Co increased its stake in shares of Thermo Fisher Scientific by 57,845.0% during the fourth quarter. Auto Owners Insurance Co now owns 2,427,896 shares of the medical research company’s stock valued at $1,406,844,000 after buying an additional 2,423,706 shares during the period. Union Savings Bank bought a new position in shares of Thermo Fisher Scientific during the fourth quarter valued at approximately $856,000. Bayban purchased a new stake in Thermo Fisher Scientific in the fourth quarter worth $93,000. Finally, Pure Financial Advisors LLC boosted its holdings in Thermo Fisher Scientific by 6.2% in the fourth quarter. Pure Financial Advisors LLC now owns 1,407 shares of the medical research company’s stock valued at $815,000 after acquiring an additional 82 shares in the last quarter. Hedge funds and other institutional investors own 89.23% of the company’s stock.

Thermo Fisher Scientific Stock Up 0.3%

NYSE:TMO opened at $465.98 on Friday. The company has a debt-to-equity ratio of 0.77, a current ratio of 1.53 and a quick ratio of 1.15. The firm’s 50-day moving average price is $476.59 and its 200-day moving average price is $523.32. The company has a market capitalization of $173.17 billion, a PE ratio of 25.62, a P/E/G ratio of 2.06 and a beta of 0.88. Thermo Fisher Scientific Inc. has a 1-year low of $390.50 and a 1-year high of $643.99.

Thermo Fisher Scientific (NYSE:TMO) last issued its quarterly earnings results on Thursday, April 23rd. The medical research company reported $5.44 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $5.25 by $0.19. The company had revenue of $11.01 billion during the quarter, compared to analysts’ expectations of $10.86 billion. Thermo Fisher Scientific had a net margin of 15.15% and a return on equity of 16.86%. Thermo Fisher Scientific’s revenue was up 6.2% on a year-over-year basis. During the same period last year, the company posted $5.15 EPS. Thermo Fisher Scientific has set its FY 2026 guidance at 24.640-25.120 EPS. On average, equities analysts predict that Thermo Fisher Scientific Inc. will post 24.85 EPS for the current fiscal year.

Thermo Fisher Scientific Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Wednesday, July 15th. Stockholders of record on Monday, June 15th will be given a $0.47 dividend. This represents a $1.88 dividend on an annualized basis and a dividend yield of 0.4%. The ex-dividend date of this dividend is Monday, June 15th. Thermo Fisher Scientific’s payout ratio is currently 10.34%.

Analysts Set New Price Targets

TMO has been the subject of several research reports. Wells Fargo & Company decreased their price objective on shares of Thermo Fisher Scientific from $675.00 to $615.00 and set an “overweight” rating for the company in a report on Friday, May 8th. Barclays reduced their price target on shares of Thermo Fisher Scientific from $650.00 to $625.00 and set an “overweight” rating on the stock in a research report on Tuesday, April 14th. Piper Sandler initiated coverage on shares of Thermo Fisher Scientific in a research note on Thursday, June 11th. They issued a “neutral” rating and a $510.00 price target for the company. Stifel Nicolaus cut their price objective on Thermo Fisher Scientific from $700.00 to $600.00 and set a “buy” rating on the stock in a research report on Friday, April 24th. Finally, Wolfe Research assumed coverage on Thermo Fisher Scientific in a report on Tuesday, June 2nd. They set an “outperform” rating and a $535.00 target price on the stock. Two analysts have rated the stock with a Strong Buy rating, eighteen have given a Buy rating and five have assigned a Hold rating to the company’s stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $608.95.

Insiders Place Their Bets

In related news, COO Gianluca Pettiti sold 400 shares of the firm’s stock in a transaction that occurred on Monday, April 27th. The stock was sold at an average price of $462.66, for a total transaction of $185,064.00. Following the completion of the transaction, the chief operating officer owned 25,051 shares of the company’s stock, valued at $11,590,095.66. This trade represents a 1.57% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 0.33% of the stock is currently owned by company insiders.

About Thermo Fisher Scientific

Thermo Fisher Scientific (NYSE: TMO) is a global provider of scientific instrumentation, reagents and consumables, software, and services that support research, clinical, and industrial laboratories. The company supplies analytical instruments and laboratory equipment, life sciences reagents and kits, specialty diagnostics, and a broad range of consumables used by researchers, clinicians, and manufacturers. Its offerings also include laboratory information management and data-analysis software, as well as service solutions such as instrument maintenance, validation, and logistics that help customers run complex workflows efficiently.

Thermo Fisher operates through multiple business areas that broadly cover life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services, including contract development and manufacturing for pharmaceutical and biotechnology companies.